Results 91 to 100 of about 33,449 (240)

MDMA Decreases Gluatamic Acid Decarboxylase (GAD) 67-Immunoreactive Neurons in the Hippocampus and Increases Seizure Susceptibility: Role for Glutamate [PDF]

, 2016
3,4-Methylenedioxy-methamphetamine (MDMA) is a unique psychostimulant that continues to be a popular drug of abuse. It has been well documented that MDMA reduces markers of 5-HT axon terminals in rodents, as well as humans.
Gudelsky, Gary A., Herman, James P., Huff, Courtney L., Morano, Rachel L., Yamamoto, Bryan K.   +4 more
core   +1 more source

Drug sellers' use of a drug checking service amid the overdose crisis in British Columbia, Canada

Addiction, EarlyView.
Abstract Aims This study examined the use of a drug checking service by drug sellers in British Columbia, Canada, to assess motivations for service use and substances intended for distribution, focusing on risks associated with an unstable illicit drug market.
Pablo Gonzalez‐Nieto, Bruce Wallace, Collin Kielty, Irene Shkolnikov, Ava Margolese, Jaime Arredondo Sanchez Lira, Chris Gill, Dennis Hore   +7 more
wiley   +1 more source

The feasibility of mindfulness‐based relapse prevention for adults with substance use disorders (illicit drugs) in a Chinese population: A pilot randomized controlled trial

Addiction, EarlyView.
Abstract Background and aims Mindfulness‐based relapse prevention (MBRP) has been shown to be beneficial to individuals with substance use disorder (SUD) in the West. The current pilot study aimed at testing the feasibility of MBRP in a Chinese population.
Ka Tsun Ting, Ivan Chun Him Leung, Dicken Cheong Chun Chan, Ken On Tai Yu, Wai Kwong Tang, Fu Chan, Alan Ka Lam Tang, Helen Shuk Wah Ma, Benjamin Hon Kei Yip, Daisy Dexing Zhang, Sarah Bowen, Samuel Yeung Shan Wong   +11 more
wiley   +1 more source

Safety pharmacology of acute mescaline administration in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Aims Psychedelics, including mescaline, may serve as novel treatments for depression and anxiety. However, data is scarce on the safety of mescaline. Methods The present pooled analysis included two double‐blind, randomized, placebo‐controlled studies with a total of 48 participants and 96 mescaline administrations. Single oral‐dose administrations (n =
Aaron Klaiber, Mélusine Humbert‐Droz, Laura Ley, Yasmin Schmid, Matthias E. Liechti   +4 more
wiley   +1 more source

The Australia story: Current status and future challenges for the clinical applications of psychedelics

British Journal of Pharmacology, EarlyView.
Abstract The past decade has seen a huge increase in clinical research with psychedelic drugs and 3,4‐methylenedioxymethamphetamine (MDMA), which have revealed great potential for treating mental health conditions. Given this progress in research, as well as the current unmet clinical need of millions of patients, in 2023, the Australian Therapeutic ...
David J Nutt, Peter Hunt, Anne Katrin Schlag, Paul Fitzgerald   +3 more
wiley   +1 more source

3,4-Methylenedioxymethamphetamine: From Dangerous Party Drug to Potential Therapeutic Agent

Quality in Sport
Introduction and aim of the study: 3,4-methylenedioxymethamphetamine (MDMA) is a stimulant drug with widespread consumption. It is used mainly in recreational settings, due to its ability to induce various pleasurable, mood-enhancing effects.
Magdalena Ostaszewska, Milena Majchrzyk, Damian Zienkiewicz, Gabriela Makulec, Karolina Domosud, Weronika Walendziak, Natalia Mordal, Kacper Ściebura, Wiktoria Wiśniewska, Anna Malczyk   +9 more
doaj   +1 more source

MDMA Impairs Response to Water Intake in Healthy Volunteers

Advances in Pharmacological Sciences, 2016
Hyponatremia is a serious complication of 3,4-methylenedioxymethamphetamine (MDMA) use. We investigated potential mechanisms in two double-blind, placebo-controlled studies.
Matthew J. Baggott, Kathleen J. Garrison, Jeremy R. Coyle, Gantt P. Galloway, Allan J. Barnes, Marilyn A. Huestis, John E. Mendelson   +6 more
doaj   +1 more source

Psychedelics, entactogens and psychoplastogens for depression and related disorders

British Journal of Pharmacology, EarlyView.
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley   +1 more source

Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology

British Journal of Pharmacology, EarlyView.
Theorized mechanism of dopamine homeostasis restoration in the nucleus accumbens core induced by a psychedelic intervention. Abstract Psychedelics have garnered great attention in recent years as treatments for major depressive disorder (MDD) and treatment‐resistant depression because of their ability to alter consciousness and afflicted cognitive ...
Lucas Wittenkeller, Gary Gudelsky, T. John Winhusen, Davide Amato   +3 more
wiley   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source